Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Comenzo

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Biochemistry and Biophysics Reports|May 7, 2025
Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cellsP Zhou, X Ma, S Scalia, et al.
Leukemia|December 2, 2005
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantationR L Comenzo, H Hassoun, T Kewalramani, et al.
Transfusion|March 3, 1998
Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and applicationR L Comenzo, D Michelle, M LeBlanc, et al.
Leukemia|September 28, 2012
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosisH Landau, H Hassoun, M A Rosenzweig, et al.
Biochimica Et Biophysica Acta|June 4, 1999
Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chainJ Wally, G Kica, Y Zhang, et al.
Bone Marrow Transplantation|January 23, 2002
Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosisG Akpek, G Lenz, S M Lee, et al.
Leukemia|July 16, 2016
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisG Merlini, I Lousada, Y Ando, et al.
British Journal of Haematology|August 12, 2008
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasoneD Lebovic, J Hoffman, B M Levine, et al.
Blood|October 1, 1996
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patientsR L Comenzo, E Vosburgh, R W Simms, et al.
British Journal of Haematology|March 23, 1999
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisR L Comenzo, V Sanchorawala, C Fisher, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Biochemistry and Biophysics Reports|May 7, 2025
Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cellsP Zhou, X Ma, S Scalia, et al.
Leukemia|December 2, 2005
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantationR L Comenzo, H Hassoun, T Kewalramani, et al.
Transfusion|March 3, 1998
Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and applicationR L Comenzo, D Michelle, M LeBlanc, et al.
Leukemia|September 28, 2012
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosisH Landau, H Hassoun, M A Rosenzweig, et al.
Biochimica Et Biophysica Acta|June 4, 1999
Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chainJ Wally, G Kica, Y Zhang, et al.
Bone Marrow Transplantation|January 23, 2002
Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosisG Akpek, G Lenz, S M Lee, et al.
Leukemia|July 16, 2016
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisG Merlini, I Lousada, Y Ando, et al.
British Journal of Haematology|August 12, 2008
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasoneD Lebovic, J Hoffman, B M Levine, et al.
Blood|October 1, 1996
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patientsR L Comenzo, E Vosburgh, R W Simms, et al.
British Journal of Haematology|March 23, 1999
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisR L Comenzo, V Sanchorawala, C Fisher, et al.
Pageof 5